{
  "id": 5494075,
  "title": "Relay Therapeutics CFO Sells 17,717 Shares for $350,000",
  "url": "https://urgent.news/2026/09/02/relay-therapeutics-cfo-sells-17-717-shares-for-350-000-5494075",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T17:20:01.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/relay-therapeutics-cfo-sells-17-172001017.html"
  },
  "original_language": "en",
  "account": "Thomas Catinazzo, the CFO of Relay Therapeutics, sold 17,717 shares of the company's stock on August 14, 2026, for a total of $350,000. This sale was conducted through a pre-arranged trading plan adopted in October 2025, ensuring structured liquidity unaffected by corporate developments. After the transaction, Catinazzo retains 140,568 shares, representing a 11% reduction in his direct stake. As of the Aug. 17, 2026 market close, the remaining shares are valued at approximately $2.9 million. Despite the significant increase in the company's stock price over the past year, analysts still expect further gains. The Motley Fool's Stock Advisor analysts rate Relay Therapeutics as a buy, with a median price target of $26, indicating a potential gain of 40.9% from the current stock price.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Relay Therapeutics CFO Sells 17,717 Shares for $350,000",
        "url": "https://urgent.news/2026/09/02/relay-therapeutics-cfo-sells-17-717-shares-for-350-000-5140710",
        "published": "2026-09-02T17:00:01.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "Relay Therapeutics CFO Sells 17,717 Shares for $350,000",
        "url": "https://urgent.news/2026/09/02/relay-therapeutics-cfo-sells-17-717-shares-for-350-000",
        "published": "2026-09-02T17:20:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}